Avanos Medical

AVNS

Market cap $549M

Avanos Medical, Inc. (AVNS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

ALPHARETTA, Ga., Jan. 7, 2026 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) today announced that Dave Pacitti, chief executive officer, will present at the 44th Annual J.P.

AVNS, ALG and CLMB have been added to the Zacks Rank #5 (Strong Sell) List on January 6th, 2026.

AVNS, ADM and OZK have been added to the Zacks Rank #5 (Strong Sell) List on Dec. 17, 2025.

Avanos Medical (AVNS) reported earnings 30 days ago. What's next for the stock?

Avanos Medical posts a Q3 earnings and sales beat, boosts 2025 outlook as Specialty Nutrition drives solid double-digit growth.

Avanos Medical, Inc. ( AVNS ) Q3 2025 Earnings Call November 5, 2025 9:00 AM EST Company Participants Jason Pickett - Vice President of Tax & Treasurer David Pacitti - CEO & Director Scott Galovan - CFO & Senior VP Conference Call Participants Daniel Stauder - Citizens JMP Securities, LLC, Research Division Presentation Operator Good morning, ladies and gentlemen, and welcome to the Avanos Third Quarter 2025 Earnings Conference Call. [Operator Instructions] This call is being recorded on Wednesday, November 5, 2025.

Avanos Medical (AVNS) came out with quarterly earnings of $0.22 per share, beating the Zacks Consensus Estimate of $0.16 per share. This compares to earnings of $0.36 per share a year ago.

Delivered double-digit growth in Specialty Nutrition Systems segment Closed acquisition of Nexus Medical, providing a complementary technology for the Specialty Nutrition Systems segment Raising and narrowing top-line guidance and adjusted EPS guidance for the full year ALPHARETTA, Ga. , Nov. 5, 2025 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) today reported third quarter 2025 financial results.

ALPHARETTA, Ga. , Oct. 27, 2025 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) will webcast its conference call discussing financial results and business highlights for the second quarter 2025 on Wed.